Eiger BioPharmaceuticals

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company headquartered in Palo Alto, California, specializing in the development of targeted therapies for rare and ultra-rare diseases. The company's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection, a life-threatening condition with significant unmet medical needs. Eiger's pipeline also includes Lambda, which is being evaluated in Phase 2 trials for HDV treatment, and Lonafarnib is being explored for its potential use in treating progeria and progeroid laminopathies. Additionally, Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia, is also undergoing clinical evaluation for congenital hyperinsulinism. Eiger's strategic focus is on efficient drug development to deliver safe and effective therapies to patients suffering from these serious conditions.

Kevin Kaster

Vice President, Patents and Licensing

David Apelian Ph.D

CEO and Board Member

1 past transactions

Celladon

Acquisition in 2015
Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.